US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Panbela Therapeutics, Inc. - Common Stock (OP:PBLA)

0.0111 UNCHANGED
Last Price Updated: 1:15 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Panbela Therapeutics, Inc. - Common Stock

News headline image
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024 ↗
PBLA stock results show that Panbela Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American 
From Panbela Therapeutics, Inc.
Via GlobeNewswire